US20020064549A1 - Insulin supplemented infant formula - Google Patents

Insulin supplemented infant formula Download PDF

Info

Publication number
US20020064549A1
US20020064549A1 US10/015,782 US1578201A US2002064549A1 US 20020064549 A1 US20020064549 A1 US 20020064549A1 US 1578201 A US1578201 A US 1578201A US 2002064549 A1 US2002064549 A1 US 2002064549A1
Authority
US
United States
Prior art keywords
insulin
infant formula
infant
solution
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/015,782
Other versions
US6399090B1 (en
Inventor
Naim Shehadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUTRINIA Ltd
Original Assignee
Insotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012594 external-priority patent/WO1999062558A1/en
Assigned to INSOTECH LTD. reassignment INSOTECH LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHEHADEH, NAIM
Application filed by Insotech Ltd filed Critical Insotech Ltd
Priority to US10/015,782 priority Critical patent/US6399090B1/en
Publication of US20020064549A1 publication Critical patent/US20020064549A1/en
Application granted granted Critical
Publication of US6399090B1 publication Critical patent/US6399090B1/en
Assigned to NUTRINIA LTD. reassignment NUTRINIA LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INSOTECH LTD.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Definitions

  • the present invention relates to an infant formula and, more particularly, to an insulin supplemented infant formula.
  • Type-1 diabetes which is insulin dependent diabetes mellitus (IDDM)
  • IDDM insulin dependent diabetes mellitus
  • IDDM insulin dependent diabetes mellitus
  • the etiology is multifactorial, with genetic and environmental factors contributing to the autoimmune destruction of the ⁇ cells.
  • concordance for IDDM in monozygotic twins is not more than 30-50% (7) and that 90% of patients with newly diagnosed IDDM do not have an affected first-degree relative having IDDM (8), as well as the sudden increase in incidence of IDDM witnessed over the last ten years (9), have been taken as indication of the importance of environmental factors in triggering the development of the autoimmune process in genetically susceptible individuals.
  • type I diabetes is related to cow's milk consumption and neonatal feeding practices (2,10).
  • case-control studies including a study conducted in the Juvenile Diabetes Unit of the Rambam Medical Center, Haifa, Israel
  • patients with type I diabetes were more likely to have been breast-fed for less than 3 months and to have been exposed to cow's milk proteins before 3 months of age (3).
  • the immune system of patients with IDDM recognizes cow's milk proteins, as demonstrated by antibodies assays and lymphocytes activity tests (11).
  • an infant formula in a powder or solution form comprising nutritional components and an insulin supplement such that when the infant formula is fed to an infant a chance of the infant of developing diabetes is reduced; wherein said insulin is in a concentration range of about 1,000 to 100,000 micro units/100 ml of solution or 8,300-750,000 micro units/100 grams of powder.
  • a method of feeding an infant comprising the steps of dissolving an infant formula powder containing nutritional components and an insulin supplement in water for obtaining a solution including the nutritional components and the insulin supplement and feeding the infant with the solution thereby reducing a chance of the infant of developing diabetes; wherein said insulin is in a concentration range of about 1,000 to 100,000 micro units/100 ml of solution or 8,300-75,0000 micro units/100 grams of powder.
  • the insulin is recombinant insulin.
  • the insulin is synthetic.
  • the insulin is purified natural insulin.
  • the insulin is biologically active.
  • the insulin is in a concentration range of about 17,000 to 400,000 ⁇ U per 100 grams of said powder or 2,000-55,000 ⁇ U per 100 milliliters of said solution.
  • the insulin has an amino acid sequence of human insulin.
  • At least some of the nutritional components are derived from milk or soy.
  • the present invention successfully addresses the shortcomings of the presently known configurations by providing an infant formula which is more similar to human milk, protects from the development of Type-1 diabetes and improve the development and maturation of infants intestine.
  • the present invention is of an infant formula supplemented with insulin, preferably human insulin, which can be used to feed infants. Specifically, the present invention can be used to protect infants of syndromes associated with feed devoid of insulin fed to them in the first year of their lives. The present invention renders infant formulas more similar to human milk.
  • Addition of insulin to infant formula leads for the following beneficial effects. First, it renders the infant formula more similar to human milk. Second, it protects from the development of Type-1 diabetes. Third, it improve the development and maturation of infants intestine. The addition of insulin to infant formula is safe for at least two reasons. First, the concentration of insulin is selected similar to that found in human milk. Second, oral insulin administration is already used in several human trials (17).
  • an infant formula in a powder or solution form which formula includes nutritional components and an insulin supplement.
  • a method of feeding an infant is effected by executing the following steps. First an infant formula powder containing nutritional components and an insulin supplement is solubilized in water for obtaining a solution including the nutritional components and the insulin supplement. Second, the solution is fed to the infant.
  • the nutritional components may include milk or soy derived nutritional components. They may additionally include one or more of the following ingredients: lactose, vegetable oils, skimmed milk powder, whey protein concentrate, Sodium, Calcium, Phosphorus, Potassium, Chloride, Iron, Magnesium, Taurine, Vitamins, Glucose syrup, soy protein isolate, Sucrose, Maltodextrine, Methionine, Taurine, Carnitine, and trace elements.
  • the insulin is selected from the following insulin types: recombinant insulin, synthetic insulin, purified natural insulin, biologically active insulin and insulin having an amino acid sequence of human insulin (e.g., human insulin). Some of these types are overlapping and therefore the insulin of choice may be categorized to more than a single type of the types listed.
  • Human recombinant insulin is available in a pure form from Eli Lilly & Co, USA.
  • Human natural purified insulin is available in a pure form from Novo Nordisk, Denmark. Crude extracts may also be useful, depending on the method of their manufacturing.
  • Synthetic insulin may be manufactured using commercially available building units for Boc and Fmoc chemistry peptide synthesis, as well known in the art.
  • the concentration of the insulin in the solution is similar to the concentration in human milk.
  • the insulin concentration is in the range of about 25000-75000 ⁇ U per 100 grams of the powder (which is diluted about 7.5 fold to form the solution) or 3000-10000 ⁇ U per 100 milliliters of the solution, preferably 3000-6000, optimally about 4200 ⁇ U per 100 milliliters of the solution.
  • insulin concentration is significantly higher in human milk (about 42 ⁇ U/ml) compared with commercial fresh cow milk (about 17 ⁇ U/ml) and infant formulas (about 4-12 ⁇ U/ml). Insulin levels in infant formulas is very low and is similar to the levels recorded for negative control solution (0.5% bovine serum albumin solution, about 6 ⁇ U/ml).
  • Tables 2 and 3 below provide exemplary compositions of dry and in solution milk- and soy-bases infant formulas according to the present invention.
  • the formula comprises the following ingredients: lactose, vegetable oils, skimmed milk powder, whey protein concentrate, Sodium, Calcium, Phosphorus, Potassium, Chloride, Iron, Magnesium, Taurine, Vitamins and Insulin.
  • TABLE 2 Powder Solution Unit 100 g 100 ml General Comp. Protein gram 11.1 1.5 Fat gram 25.9 3.5 Lactose gram 55.5 7.5 Water gram 2.5 — Ash gram 2.06 0.27 Insulin ⁇ U 22500-75000 3000-10000 Vitamins Vitamin A I.U. 1500 200 Vitamin D I.U.
  • Vitamin B mg 6 0.81 Vitamin K ⁇ g 15 2.01 Vitamin B1 ⁇ g 350 47.03 Vitamin B2 ⁇ g 450 60 Vitamin B6 ⁇ g 222 30 Vitamin B12 ⁇ g 0.66 0.09 Niacin mg 2 0.27 Folic Acid ⁇ g 45 6 Calcium mg 4.44 0.06 Pantothenate Biotin ⁇ g 11 1.5 Vitamin C mg 45 6.08 Minerals Calcium mg 326 44 Phosphorus mg 219 29.6 Magnesium mg 37 5 Iron mg 7.4 1 Sodium mg 120.7 16.3 Potassium mg 373 50 Cal ratio — 1.49 1.49 Amino Acid Profile Alanine mg 522 69.6 Arginine mg 368 49.1 Asparatic Acid mg 11.10 1.5 Cystine mg 191 25.5 Glutamic Acid mg 1423 189.7 Glycine mg 244 32.5 Histidine mg 262 34.9 Isoleucine mg 761 101.5 Leucine mg 12.20 1.62 Lysine mg 10.00 1.3 Methionine mg 270 36 Phenylalanine mg 461 6
  • the formula comprises the following ingredients: Glucose syrup, vegetable oils, soy protein isolate, Sucrose, Maltodextrine, Sodium, Calcium, Phosphorus, Potassium, chloride, Iron, Magnesium, Vitamins, Methionine, Taurine, Camitine, trace elements and Insulin.
  • TABLE 3 Powder Solution Unit 100 g 100 ml General Comp. Protein gram 15 1.98 Fat gram 27.54 3.64 Carbohydrate gram 51.5 6.8 Linoleic Acid gram 4.5 0.6 Insulin ⁇ U 22500-75000 3000-10000 Vitamins Vitamin A I.U. 1500 198 Vitamin D I.U. 300 39.7 Vitamin E I.U.
  • Vitamin C mg 65 8.6 Vitamin K ⁇ g 77 10.2 Vitamin B1 ⁇ g 345 45.6 Vitamin B2 ⁇ g 445 58.9 Vitamin B6 ⁇ g 327 43.3 Vitamin B12 ⁇ g 1.5 0.2 Niacin mg 7 0.93 Folic Acid ⁇ g 76 10 Pantothenic Acid ⁇ g 4.5 0.6 Biotin ⁇ g 25 3.3 Choline mg 58 7.7 Minerals Calcium mg 500 66.2 Phosphoms mg 300 39.7 Magnesium mg 45 6 Iron mg 9.2 1.2 Zinc mg 4 0.53 Manganese pg 150 19.8 Copper ⁇ g 400 53 Iodine ⁇ g 77 10.2 Sodium mg 200 26.5 Potassium mg 546 72.2 Chloride mg 400 53 Inositol mg 25 3.3 Carnitine mg 10 1.3 Ca/P ratio 1.67 1.67 Amino Acid Profile Alanine mg 640 85.3 Arginine mg 497 6.5 Aspartic Acid mg 1385 184.7 Cystine mg 242 32.3 Glutamic Acid mg 3065 4
  • Eisenbarth G Autoimmune beta cell insufficiency: Diabetes mellitus type 1.
  • Fava D Leslie D, Pozzilli P. Relationship between dairy product consumption and incidence of IDDM in childhood in Italy. Diabetes Care 17:1488-1490, 1994.

Abstract

An infant formula in a powder or solution form including nutritional components and an insulin supplement. A method of feeding an infant including the steps of dissolving an infant formula powder containing nutritional components and an insulin supplement in water for obtaining a solution including said nutritional components and said insulin supplement and feeding the infant with the solution.

Description

  • This application is a continuation in part of U.S. patent application Ser. No. 09/701,652 filed in Nov. 30, 2000.[0001]
    • FIELD AND BACKGROUND OF THE INVENTION
  • The present invention relates to an infant formula and, more particularly, to an insulin supplemented infant formula. [0002]
  • Breastfeeding, the natural feeding mode, has multiple beneficial effects on the infant. First, it is known to be the most suitable diet for infant's nutritional requirements. Second, it provides the infant with immune protection against a wide range of infection related diseases (1). Third, as it contains active insulin molecules it protects the infant against the development of Type-1 diabetes (2-3). Fourth, insulin present in milk enhances small intestinal growth and development (4). [0003]
  • Type-1 diabetes, which is insulin dependent diabetes mellitus (IDDM), is the consequence of progressive autoimmune pancreatic β cell destruction during an initially asymptomatic period that may extend many years (5-6). The etiology is multifactorial, with genetic and environmental factors contributing to the autoimmune destruction of the β cells. The fact that concordance for IDDM in monozygotic twins is not more than 30-50% (7) and that 90% of patients with newly diagnosed IDDM do not have an affected first-degree relative having IDDM (8), as well as the sudden increase in incidence of IDDM witnessed over the last ten years (9), have been taken as indication of the importance of environmental factors in triggering the development of the autoimmune process in genetically susceptible individuals. [0004]
  • Many studies show that type I diabetes is related to cow's milk consumption and neonatal feeding practices (2,10). In the case-control studies (including a study conducted in the Juvenile Diabetes Unit of the Rambam Medical Center, Haifa, Israel), patients with type I diabetes were more likely to have been breast-fed for less than 3 months and to have been exposed to cow's milk proteins before 3 months of age (3). Moreover, the immune system of patients with IDDM recognizes cow's milk proteins, as demonstrated by antibodies assays and lymphocytes activity tests (11). These data emphasize the importance of diet and orally administered proteins on the development of autoimmune diabetes. [0005]
  • In animal models, It has been shown that oral feeding of a specific antigen can suppress the immune system and cause an antigen-specific reduction in many types of immune responses, including T cell proliferation; delayed type hypersensitivity, and antibody production (12-15). Oral administration of insulin generates active cellular mechanisms that suppress the development of autoimmune diabetes (16). These results have paved the way to the “oral tolerance approach” and oral insulin treatment is already taking place in human trials planned to prevent type 1 diabetes in high risk groups (17). [0006]
  • As shown below, prior art infant formulas, although attempting to mimic as much as possible breast milk, are very low in immunologically recognizable insulin as compared with human milk. The level of active insulin in these formulas is probably zero, due to the harsh conditions associated with their manufacture. [0007]
  • There is thus a widely recognized need for, and it would be highly advantageous to have, an infant formula supplemented with insulin. [0008]
    • SUMMARY OF THE INVENTION
  • According to one aspect of the present invention there is provided an infant formula in a powder or solution form comprising nutritional components and an insulin supplement such that when the infant formula is fed to an infant a chance of the infant of developing diabetes is reduced; wherein said insulin is in a concentration range of about 1,000 to 100,000 micro units/100 ml of solution or 8,300-750,000 micro units/100 grams of powder. [0009]
  • According to another aspect of the present invention there is provided a method of feeding an infant comprising the steps of dissolving an infant formula powder containing nutritional components and an insulin supplement in water for obtaining a solution including the nutritional components and the insulin supplement and feeding the infant with the solution thereby reducing a chance of the infant of developing diabetes; wherein said insulin is in a concentration range of about 1,000 to 100,000 micro units/100 ml of solution or 8,300-75,0000 micro units/100 grams of powder. [0010]
  • According to further features in preferred embodiments of the invention described below, the insulin is recombinant insulin. [0011]
  • According to still further features in the described preferred embodiments the insulin is synthetic. [0012]
  • According to still further features in the described preferred embodiments the insulin is purified natural insulin. [0013]
  • According to still further features in the described preferred embodiments the insulin is biologically active. [0014]
  • According to still further features in the described preferred embodiments the insulin is in a concentration range of about 17,000 to 400,000 μU per 100 grams of said powder or 2,000-55,000 μU per 100 milliliters of said solution. [0015]
  • According to still further features in the described preferred embodiments the insulin has an amino acid sequence of human insulin. [0016]
  • According to still further features in the described preferred embodiments at least some of the nutritional components are derived from milk or soy. [0017]
  • The present invention successfully addresses the shortcomings of the presently known configurations by providing an infant formula which is more similar to human milk, protects from the development of Type-1 diabetes and improve the development and maturation of infants intestine. [0018]
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention is of an infant formula supplemented with insulin, preferably human insulin, which can be used to feed infants. Specifically, the present invention can be used to protect infants of syndromes associated with feed devoid of insulin fed to them in the first year of their lives. The present invention renders infant formulas more similar to human milk. [0019]
  • The principles and operation of an infant formula according to the present invention may be better understood with reference to the drawings and accompanying descriptions. [0020]
  • Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting. [0021]
  • Epidemiological and experimental animal data suggest that insulin content in infant diet may play an important role in preventing autoimmune diabetes and improving intestinal development. [0022]
  • It is shown in the Examples section hereinunder that the level of immunologically recognized insulin in a variety of commonly used infant formulas is very low, at least four to ten times lower as compared with human milk, probably even lower. Although not tested, the level of active insulin in such formulas is expected to be zero due to the harsh conditions associated with their manufacture. Soy-based infant formulas, are devoid of milk content, and are therefore completely devoid of both immunologically recognizable insulin, not to mention active insulin. [0023]
  • Moreover, it has been shown that exposure to bovine insulin present in fresh cow milk, which differs from human insulin only by three amino acids, may break the tolerance to insulin and lead to autoimmune diabetes (18). [0024]
  • To overcome these two obstacles in infant feeding: the lack of insulin in infant formulas and the risk to break immune tolerance to insulin when using fresh cow milk, it is herein suggest for the first time to add human insulin to infant formula. [0025]
  • Addition of insulin to infant formula leads for the following beneficial effects. First, it renders the infant formula more similar to human milk. Second, it protects from the development of Type-1 diabetes. Third, it improve the development and maturation of infants intestine. The addition of insulin to infant formula is safe for at least two reasons. First, the concentration of insulin is selected similar to that found in human milk. Second, oral insulin administration is already used in several human trials (17). [0026]
  • Thus, in accordance with one aspect of the present invention there is provided an infant formula in a powder or solution form which formula includes nutritional components and an insulin supplement. [0027]
  • In accordance with another aspect of the present invention there is provided a method of feeding an infant. The method is effected by executing the following steps. First an infant formula powder containing nutritional components and an insulin supplement is solubilized in water for obtaining a solution including the nutritional components and the insulin supplement. Second, the solution is fed to the infant. [0028]
  • As exemplified in the Examples section below, the nutritional components may include milk or soy derived nutritional components. They may additionally include one or more of the following ingredients: lactose, vegetable oils, skimmed milk powder, whey protein concentrate, Sodium, Calcium, Phosphorus, Potassium, Chloride, Iron, Magnesium, Taurine, Vitamins, Glucose syrup, soy protein isolate, Sucrose, Maltodextrine, Methionine, Taurine, Carnitine, and trace elements. [0029]
  • According to a preferred embodiment of the present invention, the insulin is selected from the following insulin types: recombinant insulin, synthetic insulin, purified natural insulin, biologically active insulin and insulin having an amino acid sequence of human insulin (e.g., human insulin). Some of these types are overlapping and therefore the insulin of choice may be categorized to more than a single type of the types listed. Human recombinant insulin is available in a pure form from Eli Lilly & Co, USA. Human natural purified insulin is available in a pure form from Novo Nordisk, Denmark. Crude extracts may also be useful, depending on the method of their manufacturing. Synthetic insulin may be manufactured using commercially available building units for Boc and Fmoc chemistry peptide synthesis, as well known in the art. [0030]
  • According to another preferred embodiment of the present invention the concentration of the insulin in the solution is similar to the concentration in human milk. Thus, according to a preferred embodiment the insulin concentration is in the range of about 25000-75000 μU per 100 grams of the powder (which is diluted about 7.5 fold to form the solution) or 3000-10000 μU per 100 milliliters of the solution, preferably 3000-6000, optimally about 4200 μU per 100 milliliters of the solution. [0031]
    • EXAMPLES
  • Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion. [0032]
    • Materials and Methods
  • Milk Samples and insulin measurements: [0033]
  • Human breast milk samples were collected from mothers between the second and the 30th day after delivery of full term pregnancies. Cow milk samples were taken from pooled fresh commercially available milk. Cow milk formulas were prepared according to manufacturer instructions. All samples were stored in polypropylene tubes at −20° C. Fat-free infranatant were obtained by diluting the milk samples with PBS (10 mM KH[0034] 2PO4, 0.15 M NaCl, pH 7.4) and centrifuged at 100,000 g for 60 min. Clear infranatant were aspirated and stored at −20° C. Insulin concentrations were determined by radioimmunoassay with commercial kit (Bio Data, Sorin) using human insulin as standard.
    • Experimental Results
  • As shown in Table 1 below, insulin concentration is significantly higher in human milk (about 42 μU/ml) compared with commercial fresh cow milk (about 17 μU/ml) and infant formulas (about 4-12 μU/ml). Insulin levels in infant formulas is very low and is similar to the levels recorded for negative control solution (0.5% bovine serum albumin solution, about 6 μU/ml). [0035]
    TABLE 1
    Insulin concentration in milk samples
    Insulin Concentration
    Milk Sample (mean in μU/ml)
    Human milk, n = 29 42
    Fresh pooled cow milk, n = 4 17.08
    (Tnuvah, Israel)
    Materna Premium, n = 2 7.5
    (Trima, Israel)
    Remedia Formula, n = 3 7.0
    (Humna Milchwerke ,Germany)
    Similac, n = 2 11.85
    (Ross-Abbott, Irland)
    Enfalac Premature, n = 1 5.2
    (Mead Johnson, USA)
    Pregestimil, n = 2 3.8
    (Mead Johnson, USA)
    0.5% Bovine Serum Albumin 6.5
    solution, n = 2 (Sigma, USA)
  • Tables 2 and 3 below provide exemplary compositions of dry and in solution milk- and soy-bases infant formulas according to the present invention. [0036]
    • Infant Formula I (Milk-Based)
  • The formula comprises the following ingredients: lactose, vegetable oils, skimmed milk powder, whey protein concentrate, Sodium, Calcium, Phosphorus, Potassium, Chloride, Iron, Magnesium, Taurine, Vitamins and Insulin. [0037]
    TABLE 2
    Powder Solution
    Unit 100 g 100 ml
    General Comp.
    Protein gram 11.1 1.5
    Fat gram 25.9 3.5
    Lactose gram 55.5 7.5
    Water gram 2.5 —
    Ash gram 2.06 0.27
    Insulin μU 22500-75000 3000-10000
    Vitamins
    Vitamin A I.U. 1500 200
    Vitamin D I.U. 300 40
    Vitamin B mg 6 0.81
    Vitamin K μg 15 2.01
    Vitamin B1 μg 350 47.03
    Vitamin B2 μg 450 60
    Vitamin B6 μg 222 30
    Vitamin B12 μg 0.66 0.09
    Niacin mg 2 0.27
    Folic Acid μg 45 6
    Calcium mg 4.44 0.06
    Pantothenate
    Biotin μg 11 1.5
    Vitamin C mg 45 6.08
    Minerals
    Calcium mg 326 44
    Phosphorus mg 219 29.6
    Magnesium mg 37 5
    Iron mg 7.4 1
    Sodium mg 120.7 16.3
    Potassium mg 373 50
    Cal ratio — 1.49 1.49
    Amino Acid Profile
    Alanine mg 522 69.6
    Arginine mg 368 49.1
    Asparatic Acid mg 11.10 1.5
    Cystine mg 191 25.5
    Glutamic Acid mg 1423 189.7
    Glycine mg 244 32.5
    Histidine mg 262 34.9
    Isoleucine mg 761 101.5
    Leucine mg 12.20 1.62
    Lysine mg 10.00 1.3
    Methionine mg 270 36
    Phenylalanine mg 461 62.3
    Proline mg 962 128.3
    Serine mg 681 90.8
    Taurine mg 37 4.9
    Threonine mg 686 91.5
    Tryptophan mg 180 24
    Tyrosine mg 463 61.7
    Valine mg 775 103.3
    Fatty Acid Profile
    Caprylic (C8) % from fa 2.6 2.6
    Capric (C10) % 2.1 2.1
    Lauric (C12) % 17.5 17.5
    Meristic (C14) % 6.7 6.7
    Palmitic (C16) % 11.2 11.2
    Stearic (C18) % 11.8 11.8
    Oleic (C18:1) % 37.0 37.0
    Linoleic (C18:2) % 10.0 10.0
    Linolenic (C18:3) % 1.2 1.2
    Supplement
    Insulin μU 22500-75000 3000-10000
    • Infant Formula II (Soy-Based)
  • The formula comprises the following ingredients: Glucose syrup, vegetable oils, soy protein isolate, Sucrose, Maltodextrine, Sodium, Calcium, Phosphorus, Potassium, chloride, Iron, Magnesium, Vitamins, Methionine, Taurine, Camitine, trace elements and Insulin. [0038]
    TABLE 3
    Powder Solution
    Unit 100 g 100 ml
    General Comp.
    Protein gram 15 1.98
    Fat gram 27.54 3.64
    Carbohydrate gram 51.5 6.8
    Linoleic Acid gram 4.5 0.6
    Insulin μU 22500-75000 3000-10000
    Vitamins
    Vitamin A I.U. 1500 198
    Vitamin D I.U. 300 39.7
    Vitamin E I.U. 10 1.32
    Vitamin C mg 65 8.6
    Vitamin K μg 77 10.2
    Vitamin B1 μg 345 45.6
    Vitamin B2 μg 445 58.9
    Vitamin B6 μg 327 43.3
    Vitamin B12 μg 1.5 0.2
    Niacin mg 7 0.93
    Folic Acid μg 76 10
    Pantothenic Acid μg 4.5 0.6
    Biotin μg 25 3.3
    Choline mg 58 7.7
    Minerals
    Calcium mg 500 66.2
    Phosphoms mg 300 39.7
    Magnesium mg 45 6
    Iron mg 9.2 1.2
    Zinc mg 4 0.53
    Manganese pg 150 19.8
    Copper μg 400 53
    Iodine μg 77 10.2
    Sodium mg 200 26.5
    Potassium mg 546 72.2
    Chloride mg 400 53
    Inositol mg 25 3.3
    Carnitine mg 10 1.3
    Ca/P ratio 1.67 1.67
    Amino Acid Profile
    Alanine mg 640 85.3
    Arginine mg 497 6.5
    Aspartic Acid mg 1385 184.7
    Cystine mg 242 32.3
    Glutamic Acid mg 3065 408.7
    Glycine mg 300 40
    Histidine mg 382 50.9
    Isoleucine mg 893 119.1
    Leucine mg 1600 213.3
    Lysine mg 1360 181.3
    Methionine mg 406 54.1
    Phenylalanine mg 650 86.7
    Proline mg 1113 148.4
    Serine mg 737 98.3
    Taurine mg 51 6.8
    Threonine mg 460 61.3
    Tyrosine mg 621 82.8
    Valine mg 947 126.3
    Fatty Acid Profile
    Caprylic (C8) % from fa 2.6 2.6
    Capric (C10) % 2.1 2.1
    Lauric (C12) % 17.5 17.5
    Meristic (C14) % 6.7 6.7
    Palmitic (C16) % 11.2 11.2
    Stearic (C18) % 11.8 11.8
    Oleic (C18:1) % 37.0 37.0
    Linoleic (C18:2) % 10.0 10.0
    Linolenic (C18:3) % 1.2 1.2
    Supplement
    Insulin μU 22500-75000 3000-40000
  • Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. [0039]
    • REFERENCES CITED
  • 1. Wold A E, Hanson L A. Defense factors in human milk. Curr Opin Gastroenterol 10:652-8, 1994. [0040]
  • 2. Kostraba J. What can epidemiology tell us about the role of infant diet in the etiology of IDDM?. Diabetes Care 17:87-91, 1994. [0041]
  • 3. Verge C, Howard N, Irwig L, Simpson J, Mackerras D, Silink M. Environmental factors in childhood IDDM. Diabetes Care 17:1381-1388, 1994. [0042]
  • 4. Shulman R J. Oral insulin increases small intestinal mass and disaccharidase activity in the newborn miniature pig. Pediatr Res 28:171-5, 1990. [0043]
  • 5. Gorsuch A N, Spencer K N, Lister J, McNally J M, Bottazzo G F, Cudworth A G: Evidence for a long prediabetic period in type 1 (insulin-dependent) Diabetes. [0044] Lancet ii:1363-1365, 1981.
  • 6. Eisenbarth G: Autoimmune beta cell insufficiency: Diabetes mellitus type 1. [0045] Triangle 23:111-124, 1984.
  • 7. Barnett A H, Eff C, Leslie R D G, Pyke D A. Diabetes in identical twins: a study of 200 pairs: [0046] Diabetologia 20:87-93, 1983.
  • 8. LaPorte R E, Cruickshanks K J. Incidence and risk factors for insulin dependent diabetes. In: National Diabetes Data Group. Diabetes in America: diabetes data compiled 1984. Bethesda, Md.: Department of health and human services, III-1-III-12. (NIH publication no. 85-1468.), 1985. [0047]
  • 9. Laron Z, Shamis I, Gordon O, Albaz Y: Increased incidence of childhood IDDM (0-17 yr) in Israel. [0048] J Ped Endocrinol Met 8:224, 1995.
  • 10. Fava D, Leslie D, Pozzilli P. Relationship between dairy product consumption and incidence of IDDM in childhood in Italy. Diabetes Care 17:1488-1490, 1994. [0049]
  • 11. Karjalainen J, Martin J M, Knip M, Ilonen J, Dosch H-M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 327:302-307, 1992. [0050]
  • 12. Weiner H L. Oral tolerance for the treatment of autoimmune diseases. Annu Rev Med 48:341-351, 1997. [0051]
  • 13. Garside P, Mowat A M. Mechanisms of oral tolerance. Crit Rev Immunol 17:119, 1997. [0052]
  • 14. Ke Y, Kapp J A. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol 156:916-21, 1996. [0053]
  • 15. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun 7:65-71, 1994. [0054]
  • 16. Zhang Z J, Davidson L, Eisenbarth G, Weiner H L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 80:10252-10256, 1991. [0055]
  • 17. Schatz D A, Rogers D G, Brouhard B H. Prevention of insulin-dependent diabetes mellitus: an overview of three trials. Cleve Clin J Med 63:270-4, 1996. [0056]
  • 18. Vaarala O, Paronen J, Otonkoski T, Akerblom H K. Cow milk feeding induces antibodies to insulin in children—A link between cow milk and Insulin-Dependent Diabetes Mellitus? Scand J Immunol 47:131-135, 1998. [0057]

Claims (24)

What is claimed is:
1. An infant formula in a powder or solution form comprising nutritional components and an insulin supplement such that when the infant formula is fed to an infant a chance of the infant of developing diabetes is reduced; wherein said insulin is in a concentration range of about 1,000 to 100,000 micro units/100 ml of solution or 8,300-750,000 micro units/100 grams of powder.
2. The infant formula of claim 1, wherein said insulin has an amino acid sequence of human insulin.
3. The infant formula of claim 1, wherein said insulin is recombinant.
4. The infant formula of claim 3, wherein said insulin has an amino acid sequence of human insulin.
5. The infant formula of claim 1, wherein said insulin is synthetic.
6. The infant formula of claim 5, wherein said insulin has an amino acid sequence of human insulin.
7. The infant formula of claim 1, wherein said insulin is purified natural insulin.
8. The infant formula of claim 7, wherein said insulin has an amino acid sequence of human insulin.
9. The infant formula of claim 1, wherein said insulin is biologically active.
10. The infant formula of claim 1, wherein said insulin is in a concentration range of about 2,000 to 55,000 micro units/100 ml of solution or 17000-400,000 micro units/100 grams of powder.
11. The infant formula of claim 1, wherein at least some of said nutritional components are derived from milk.
12. The infant formula of claim 1, wherein at least some of said nutritional components are derived from soy.
13. A method of feeding an infant comprising the steps of dissolving an infant formula powder containing nutritional components and an insulin supplement in water for obtaining a solution including said nutritional components and said insulin supplement and feeding the infant with said solution, thereby reducing a chance of the infant of developing diabetes; wherein said insulin is in a concentration range of about 1,000 to 100,000 micro units/100 ml of solution or 8,300-75,0000 micro units/100 grams of powder.
14. The method of claim 13, wherein said insulin has an amino acid sequence of human insulin.
15. The method of claim 13, wherein said insulin is recombinant.
16. The method of claim 15, wherein said insulin has an amino acid sequence of human insulin.
17. The method of claim 13, wherein said insulin is synthetic.
18. The method of claim 17, wherein said insulin has an amino acid sequence of human insulin.
19. The method of claim 13, wherein said insulin is purified natural insulin.
20. The method of claim 19, wherein said insulin has an amino acid sequence of human insulin.
21. The method of claim 13, wherein said insulin is biologically active.
22. The method of claim 13, wherein said insulin is in a concentration range of about 17,000 to 400,000 μU per 100 grams of said powder or 2,000-55,000 μU per 100 milliliters of said solution.
23. The method of claim 13, wherein at least some of said nutritional components are derived from milk.
24. The method of claim 13, wherein at least some of said nutritional components are derived from soy.
US10/015,782 1998-06-05 2001-12-17 Insulin supplemented infant formula Expired - Lifetime US6399090B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/015,782 US6399090B1 (en) 1998-06-05 2001-12-17 Insulin supplemented infant formula

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9090998A 1998-06-05 1998-06-05
USPCT/US99/12592 1999-06-03
PCT/US1999/012594 WO1999062558A1 (en) 1998-06-05 1999-06-03 Insulin supplemented infant formula
US09/701,652 US6365177B1 (en) 1998-06-05 1999-06-03 Insulin supplemented infant formula
US10/015,782 US6399090B1 (en) 1998-06-05 2001-12-17 Insulin supplemented infant formula

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/012594 Continuation-In-Part WO1999062558A1 (en) 1998-06-05 1999-06-03 Insulin supplemented infant formula
US09/701,652 Continuation-In-Part US6365177B1 (en) 1998-06-05 1999-06-03 Insulin supplemented infant formula

Publications (2)

Publication Number Publication Date
US20020064549A1 true US20020064549A1 (en) 2002-05-30
US6399090B1 US6399090B1 (en) 2002-06-04

Family

ID=27624774

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/015,782 Expired - Lifetime US6399090B1 (en) 1998-06-05 2001-12-17 Insulin supplemented infant formula

Country Status (1)

Country Link
US (1) US6399090B1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808736B2 (en) * 2001-06-07 2004-10-26 Nestec S.A. Soy hydrolysate based nutritional formulations
WO2005117951A1 (en) * 2004-06-02 2005-12-15 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
EP1659873A2 (en) * 2003-06-20 2006-05-31 Nutrinia Limited Bioactive compounds protection method and compositions containing the same
US20070248652A1 (en) * 2004-05-24 2007-10-25 Nutrinia Ltd. Nutritional Food and Feed, Compostition, Processing and Method of Use
US20080026378A1 (en) * 2006-07-28 2008-01-31 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
AU2007298649B2 (en) * 2006-07-28 2012-08-09 Al-Saqqaf, Lamya Prediction and prophylactic treatment of type 1 diabetes
US10046032B2 (en) 2016-03-24 2018-08-14 Nutrinia, Ltd. Use of insulin for promoting gastric emptying
EP3638312A4 (en) * 2017-06-12 2021-03-17 Nutrinia Ltd. Multiparticulate granulate comprising insulin
CN113080448A (en) * 2012-04-18 2021-07-09 爱儿安制药有限公司 Growth promotion in infants

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US8498729B2 (en) 2008-08-29 2013-07-30 Smp Logic Systems Llc Manufacturing execution system for use in manufacturing baby formula
WO2013179290A1 (en) 2012-05-31 2013-12-05 Nutrinia Ltd. Insulin-containing infant formula

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808736B2 (en) * 2001-06-07 2004-10-26 Nestec S.A. Soy hydrolysate based nutritional formulations
US8877232B2 (en) 2003-06-20 2014-11-04 Nutrinia Ltd. Bioactive compounds protection method and compositions containing the same
US9943485B2 (en) 2003-06-20 2018-04-17 Nutrinia Ltd. Bioactive compounds protection method and compositions containing the same
EP1659873A2 (en) * 2003-06-20 2006-05-31 Nutrinia Limited Bioactive compounds protection method and compositions containing the same
US9750699B2 (en) 2003-06-20 2017-09-05 Nutrinia Ltd. Bioactive compounds protection method and compositions containing the same
US20060147494A1 (en) * 2003-06-20 2006-07-06 Amir Barzilay Bioactive compounds protection method and compositions containing the same
EP1659873A4 (en) * 2003-06-20 2011-06-08 Nutrinia Ltd Bioactive compounds protection method and compositions containing the same
US20070248652A1 (en) * 2004-05-24 2007-10-25 Nutrinia Ltd. Nutritional Food and Feed, Compostition, Processing and Method of Use
US20070225211A1 (en) * 2004-06-02 2007-09-27 Technion Research & Developement Methods and Formulations for Increasing Intestinal Function
WO2005117951A1 (en) * 2004-06-02 2005-12-15 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
US8026211B2 (en) 2004-06-02 2011-09-27 Technion Research & Development Foundation Ltd. Methods and formulations for increasing intestinal function
US20100137393A1 (en) * 2006-07-28 2010-06-03 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
US20080026378A1 (en) * 2006-07-28 2008-01-31 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
AU2007298649B2 (en) * 2006-07-28 2012-08-09 Al-Saqqaf, Lamya Prediction and prophylactic treatment of type 1 diabetes
US8063011B2 (en) 2006-07-28 2011-11-22 Gian Franco Bottazzo Prediction and prophylactic treatment of type 1 diabetes
US10017819B2 (en) 2006-07-28 2018-07-10 Lamya Al-Saqqaf Prediction and prophylactic treatment of type 1 diabetes
CN113080448A (en) * 2012-04-18 2021-07-09 爱儿安制药有限公司 Growth promotion in infants
US10046032B2 (en) 2016-03-24 2018-08-14 Nutrinia, Ltd. Use of insulin for promoting gastric emptying
EP3638312A4 (en) * 2017-06-12 2021-03-17 Nutrinia Ltd. Multiparticulate granulate comprising insulin

Also Published As

Publication number Publication date
US6399090B1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
US6365177B1 (en) Insulin supplemented infant formula
US6399090B1 (en) Insulin supplemented infant formula
Koldovský Search for role of milk-borne biologically active peptides for the suckling
Mahe et al. Gastrojejunal kinetics and the digestion of [15N] beta-lactoglobulin and casein in humans: the influence of the nature and quantity of the protein
Rudloff et al. Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition
Park Bioactive components in goat milk
EP1073444B1 (en) A food composition and method of using same
US6221836B1 (en) Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal
AU2005332128B2 (en) Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey
JP2002517454A (en) Prophylactic and therapeutic nutritional supplements for creation / maintenance of health-protective intestinal microflora and enhancement of the immune system
Picone et al. Growth, serum biochemistries, and amino acids of term infants fed formulas with amino acid and protein concentrations similar to human milk
EP0507872B1 (en) The use of arginine as an immunostimulator
US20020050276A1 (en) Method and bottle for infant feeding
Higuchi et al. Participation of lectin in biological effects of raw winged bean seeds on rats
US20060247315A1 (en) Method of treating intestinal disorders with citrulline
Boza et al. Nutritional and Antigenic Characterization of an Enzymic Whey Protein Hydrolyzate
Mori et al. Utilization in rats of 14C-L-lysine-labeled casein browned by amino-carbonyl reaction
US20090274768A1 (en) Fraktionen aus molkepermeat und deren verwendung zur pravention und therapie des typ-2 diabetes und des metabolischen syndroms
Jordá et al. A new case of arginase deficiency in a Spanish male
Schoenemann et al. Consequences of copper deficiency are not differentially influenced by carbohydrate source in young pigs fed a dired skim milk-based diet
Lindblad et al. The intravenous and peroral requirements of amino acids during early infancy
Calvez et al. Minimal processed infant formula vs. conventional shows comparable protein quality and increased postprandial plasma amino acid kinetics in rats
Cezard et al. Effects of two protein hydrolysates on growth, nitrogen balance and small intestine adaptation in growing rats
JP2017132726A (en) Metallothionein production promoter

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSOTECH LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHEHADEH, NAIM;REEL/FRAME:012401/0675

Effective date: 20011212

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: NUTRINIA LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INSOTECH LTD.;REEL/FRAME:014797/0257

Effective date: 20031130

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12